Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 11:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 768 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Ocular Clear all
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 4 Interventional Results available

Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma

NCT00869141
View directory record Official record
Conditions
Glaucoma
Interventions
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Sep 30, 2026, 11:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Sep 30, 2026, 11:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nidek RS3000 Comparative Study

NCT01384487
View directory record Official record
Conditions
Glaucoma, Retinal Disease, Corneal Disease
Interventions
Not listed
Lead sponsor
Nidek Co. LTD.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Sep 30, 2026, 11:06 AM EDT
Active, not recruiting Phase 4 Interventional

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

NCT06865144
View directory record Official record
Conditions
Primary Open Angle Glaucoma or Ocular Hypertension
Interventions
Netarsudil ophthalmic solution 0.02%, Artificial tears
Drug
Lead sponsor
East Coast Institute for Research
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

NCT00853073
View directory record Official record
Conditions
Glaucoma
Interventions
bevacizumab, balanced salt solution
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02250651
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332345
View directory record Official record
Conditions
Ocular Hypertension
Interventions
brimonidine/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
21 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Sep 30, 2026, 11:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Topcon 3D OCT-1000 Optical Coherence Tomography System

NCT00792259
View directory record Official record
Conditions
Retinal Disease, Glaucoma
Interventions
Not listed
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
4
States / cities
Bronxville, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 30, 2026, 11:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

African Descent and Glaucoma Evaluation Study

NCT00221923
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • La Jolla, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 30, 2026, 11:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

NCT06689696
View directory record Official record
Conditions
Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
Interventions
miLens system
Device
Lead sponsor
Smartlens, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fullerton, California • Petaluma, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 30, 2026, 11:06 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Eplerenone and IOP in Healthy Adults

NCT07795762
View directory record Official record
Conditions
Intraocular Pressure (IOP), Healthy Adult
Interventions
Eplerenone, Microcrystalline Cellulose NF (placebo)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Trabodenoson, Latanoprost, Timolol
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bristol, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Sep 30, 2026, 11:06 AM EDT
Not yet recruiting No phase listed Observational

Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness

NCT06023927
View directory record Official record
Conditions
Normal Tension Glaucoma, Obstructive Sleep Apnea
Interventions
Clinical observation, diagnostic testing
Other
Lead sponsor
Northwell Health
Other
Eligibility
21 Years and older
Enrollment
100 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 30, 2026, 11:06 AM EDT
Completed No phase listed Observational Results available

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

NCT03868254
View directory record Official record
Conditions
Glaucoma
Interventions
XEN Group, Phacoemulsification
Device · Procedure
Lead sponsor
Allergan
Industry
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 30, 2026, 11:06 AM EDT
Completed No phase listed Observational

Results of Ocular Compression and Suture Release in Trabeculectomy and Combined Surgery

NCT00327405
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2006 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

NCT03891446
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, Standard of Care
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
66
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 11:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

NCT07770685
View directory record Official record
Conditions
Glaucoma
Interventions
ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 4 Interventional Results available

XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)

NCT03654885
View directory record Official record
Conditions
Glaucoma
Interventions
XEN-45 Gel Stent, Trabeculectomy
Device · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
35
States / cities
Fayetteville, Arkansas • Arcadia, California • Culver City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 2 Interventional

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

NCT00069719
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Glaucoma therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Multiple Locations Throughout the US Sponsored by Alcon of, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Sep 30, 2026, 11:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Macular Damage in Early Glaucoma and Progression

NCT02547740
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 30, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

NCT02057575
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
23
States / cities
Artesia, California • Inglewood, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 30, 2026, 11:06 AM EDT
Completed No phase listed Observational

Automated Measurement of Optic Nerve Sheath Diameter

NCT02786706
View directory record Official record
Conditions
Traumatic Brain Injury, Acute Brain Injuries, Intracranial Hypertension
Interventions
Optic nerve ultrasound
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Sep 30, 2026, 11:06 AM EDT